Navigation Links
Albemarle Reports Record Quarterly Net Sales and Operating Results
Date:4/21/2008

emand for 2008 and 2009. While general business conditions are concerning, our business fundamentals remain sound. However, we are experiencing dramatic inflation in raw materials and energy in all of our businesses that continues to pressure operating margins. We will continue to work with our customer base to pass through these rapidly escalating costs.

Earnings Call

The Company's performance for the first quarter ended March 31, 2008 will be discussed on a conference call at 8:00 AM Eastern Daylight time on April 22, 2008, which can be accessed through Albemarle's website under Investor Information at http://www.albemarle.com.

Albemarle Corporation, headquartered in Richmond, Virginia, is a leading global developer, manufacturer and marketer of highly-engineered specialty chemicals for consumer electronics; petroleum and petrochemical processing; transportation and industrial products; pharmaceuticals; agricultural products; construction and packaging materials. The Company operates in three business segments, Polymer Additives, Catalysts and Fine Chemicals and serves customers in approximately 100 countries.

Forward-Looking Statements

Some of the information presented in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Although we believe our expectations as reflected are based on reasonable assumptions within the bounds of our knowledge of our business and operations, there can be no assurance that actual results will not differ materially. Factors that could cause actual results to differ from expectations include, without limitation: the inability to pass through increases in costs and expenses for raw materials and energy; competition from other manufacturers; changes in demand for our products; the gain or loss of significant customers; fluctuations in foreign currencies; and increase
'/>"/>

SOURCE Albemarle Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Albemarle Corporations First Quarter 2008 Earnings Conference Call To Be Held April 22, 2008 at 8:00am ET
2. Albemarle Corporations First Quarter 2008 Earnings Conference Call To Be Held April 22, 2008 at 9:00am ET
3. Albemarle Raises Prices of Specialty Aluminas
4. Albemarle to Raise Prices of Dibromomethane
5. Albemarle Reports Third Quarter 2007 Results
6. Albemarle to Increase Price of Ibuprofen
7. Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008
8. Amylin Pharmaceuticals Reports First Quarter Financial Results
9. QMed, Inc. Reports First Quarter Results
10. TeamStaff, Inc. Reports Preliminary Second Quarter 2008 Results
11. Bioniche Reports the Passing of its Board Chair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...ert Pathologists Discuss the Latest Developments i...RTHFIELD, Ill., Sept. 5 /PRNewswire-USNewswire/ --...point. Molecular testing and the promise,of person...reated. Digital,slides and other imaging technolog...lege of American Pathologists is taking a leadersh...
(Date:9/5/2008)...hers explain how theoretical ,anti-cloak, could br...pt. 5 (HealthDay News) -- Just in case someone dev...cientists say they know how to uncloak the objects... Optics Express , certain materials underneath an ...o be seen again. , Researchers at Shanghai Jiao...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- Speake...y in support of the aims of the "Stand,Up to Cance... "There is not a person in our country who has no...r kills 565,000 Americans annually, and each,year ...ricans must work,together to make eradicating the ...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- U.S. c...r relief to Cuban victims of Hurricane,Gustav, whi...s., (http://www.PanAmericanRelief.org ), "Donatio...perately need,after this natural disaster," says M... Initiative at the Pan American Development Founda...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2
...may help to make people smarter by improving memor...ts, scientists found the ability to recall remembe...gum.// The scientists from the University of North...working on two theories. One is that chewing rais...
...of the growth patterns in fossil teeth has thrown ...wth and development pattern that sets human beings...an article in the issue of Nature.// Based on the ...ers from University College, London and Penn State...
... experts at the University of Alaska, sharing some... demands of cold, dry weather.// For those of us i...n and you need to take extra care. The experts say...cerine soap and limit the time you spend in the ba...
...betics face a forewarning from severe periodontal ...g to a study in the Journal of periodontology.// R... Dentistry and Medicine compared 13 type 1 diabeti...20-39th week of pregnancy to examine the effects o...
Other Medicine News:
(Date:9/3/2008)... NANJING, China, Sept. 3 /PRNewswire-FirstCall... leading manufacturer and supplier of,branded gene...ed,anti-cancer biotech product Endu (also known as... of Endu Phase IV clinical study., At the request...l study,to further validate the safety and therape...
(Date:9/3/2008)... - Long term follow up results from chronicall...nd exceed positive data obtained earlier in 2008, ...nificant and long-term antiviral effect of ... the way and strongly support move into a second g...juvant IC31(R) acting through TLR ...
(Date:9/3/2008)... BRUSSELS, Belgium and GENEVA, Sept. 3 /PRNews... a new milestone in CHO based monoclonal antibody,...ields of over 31 grams,per liter. This record leve...ve technologies: (1) a high-performance stable Sel... industry leading scientists at,Selexis SA using t...
(Date:9/3/2008)... This analysis showed that Multaq(R) (dronedaron...with atrial fibrillation or atrial flutter already... therapy, BRIDGEWATER, N.J., Sept. 3 /PRNewswire-...f the data from the ATHENA study were presented to...ropean Society of Cardiology,congress 2008, in Mun...
Breaking Medicine Technology:Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 2Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Healthy Farms Healthy Schools Grant Applications Available 19481 1Healthy Farms Healthy Schools Grant Applications Available 19481 2The American College of Cardiology American Heart Association and the Heart Rhythm Society Release Updated Cardiac Device Based Therapy Guidelines 19478 1The American College of Cardiology American Heart Association and the Heart Rhythm Society Release Updated Cardiac Device Based Therapy Guidelines 19478 2The American College of Cardiology American Heart Association and the Heart Rhythm Society Release Updated Cardiac Device Based Therapy Guidelines 19478 3The American College of Cardiology American Heart Association and the Heart Rhythm Society Release Updated Cardiac Device Based Therapy Guidelines 19478 4Novasys Medical Secures 2449 5 Million in Series D Financing to Expand Commercialization of Its Renessa 28R 29 Treatment for Incontinence in Women 5440 1Novasys Medical Secures 2449 5 Million in Series D Financing to Expand Commercialization of Its Renessa 28R 29 Treatment for Incontinence in Women 5440 2Crystal 28eye 29 ball 3A Study says visual system equipped with future seeing powers 3326 1Crystal 28eye 29 ball 3A Study says visual system equipped with future seeing powers 3326 2Crystal 28eye 29 ball 3A Study says visual system equipped with future seeing powers 3326 3
... 2007. Giaconda Ltd (ASX: GIA) today,announced tha...proved the Company,s Investigational New Drug appl...ondaR to treat patients with,Crohn,s Disease infec...(MAP). , ,The Company understands that its lead pr...tted to the FDA for this indication. There,are no ...
... 2007-Genentech and FDA notified,healthcare profes...ing tracheoesophageal (TE) fistula formation in a ...ge small cell lung,cancer (SCLC). This multicenter...al study combined chemotherapy and radiation plus,...erse events of TE,fistula (one fatal) reported in ...
Other Medicine Technology:FDA approves MyocondaR IND for MAP in Crohn's Disease 2FDA approves MyocondaR IND for MAP in Crohn's Disease 3FDA approves MyocondaR IND for MAP in Crohn's Disease 4
Tennant straight tying forceps with extra delicate smooth jaws, 6 mm tying platform, For 9-0 to 11-0 sutures. Overall length 108 mm.
Kelman - McPherson angled tying forceps is long with tying platform 10 mm, serrated handle and polished finish.
Castroviejo tying forceps, straight.
Gerl titanium tying forceps has curved shanks, smooth jaws and 6 mm long tying platform. For 8-0 to 11-0 sutures.
Medicine Products: